Cargando…

Regulation of CD19 CAR-T cell activation based on an engineered downstream transcription factor

CAR-T cells present a highly effective therapeutic option for several malignant diseases, based on their ability to recognize the selected tumor surface marker in an MHC-independent manner. This triggers cell activation and cytokine production, resulting in the killing of the cancerous cell presenti...

Descripción completa

Detalles Bibliográficos
Autores principales: Lainšček, Duško, Golob-Urbanc, Anja, Mikolič, Veronika, Pantović-Žalig, Jelica, Malenšek, Špela, Jerala, Roman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10200817/
https://www.ncbi.nlm.nih.gov/pubmed/37223115
http://dx.doi.org/10.1016/j.omto.2023.04.005
_version_ 1785045134470021120
author Lainšček, Duško
Golob-Urbanc, Anja
Mikolič, Veronika
Pantović-Žalig, Jelica
Malenšek, Špela
Jerala, Roman
author_facet Lainšček, Duško
Golob-Urbanc, Anja
Mikolič, Veronika
Pantović-Žalig, Jelica
Malenšek, Špela
Jerala, Roman
author_sort Lainšček, Duško
collection PubMed
description CAR-T cells present a highly effective therapeutic option for several malignant diseases, based on their ability to recognize the selected tumor surface marker in an MHC-independent manner. This triggers cell activation and cytokine production, resulting in the killing of the cancerous cell presenting markers recognized by the chimeric antigen receptor. CAR-T cells are highly potent serial killers that may cause serious side effects, so their activity needs to be carefully controlled. Here we designed a system to control the proliferation and activation state of CARs based on downstream NFAT transcription factors, whose activity can be regulated via chemically induced heterodimerization systems. Chemical regulators were used to either transiently trigger engineered T cell proliferation or suppress CAR-mediated activation when desired or to enhance activation of CAR-T cells upon engagement of cancer cells, shown also in vivo. Additionally, an efficient sensor to monitor activated CD19 CAR-T cells in vivo was introduced. This implementation in CAR-T cell regulation offers an efficient way for on-demand external control of CAR-T cell activity to improve their safety.
format Online
Article
Text
id pubmed-10200817
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Society of Gene & Cell Therapy
record_format MEDLINE/PubMed
spelling pubmed-102008172023-05-23 Regulation of CD19 CAR-T cell activation based on an engineered downstream transcription factor Lainšček, Duško Golob-Urbanc, Anja Mikolič, Veronika Pantović-Žalig, Jelica Malenšek, Špela Jerala, Roman Mol Ther Oncolytics Original Article CAR-T cells present a highly effective therapeutic option for several malignant diseases, based on their ability to recognize the selected tumor surface marker in an MHC-independent manner. This triggers cell activation and cytokine production, resulting in the killing of the cancerous cell presenting markers recognized by the chimeric antigen receptor. CAR-T cells are highly potent serial killers that may cause serious side effects, so their activity needs to be carefully controlled. Here we designed a system to control the proliferation and activation state of CARs based on downstream NFAT transcription factors, whose activity can be regulated via chemically induced heterodimerization systems. Chemical regulators were used to either transiently trigger engineered T cell proliferation or suppress CAR-mediated activation when desired or to enhance activation of CAR-T cells upon engagement of cancer cells, shown also in vivo. Additionally, an efficient sensor to monitor activated CD19 CAR-T cells in vivo was introduced. This implementation in CAR-T cell regulation offers an efficient way for on-demand external control of CAR-T cell activity to improve their safety. American Society of Gene & Cell Therapy 2023-04-26 /pmc/articles/PMC10200817/ /pubmed/37223115 http://dx.doi.org/10.1016/j.omto.2023.04.005 Text en © 2023 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Original Article
Lainšček, Duško
Golob-Urbanc, Anja
Mikolič, Veronika
Pantović-Žalig, Jelica
Malenšek, Špela
Jerala, Roman
Regulation of CD19 CAR-T cell activation based on an engineered downstream transcription factor
title Regulation of CD19 CAR-T cell activation based on an engineered downstream transcription factor
title_full Regulation of CD19 CAR-T cell activation based on an engineered downstream transcription factor
title_fullStr Regulation of CD19 CAR-T cell activation based on an engineered downstream transcription factor
title_full_unstemmed Regulation of CD19 CAR-T cell activation based on an engineered downstream transcription factor
title_short Regulation of CD19 CAR-T cell activation based on an engineered downstream transcription factor
title_sort regulation of cd19 car-t cell activation based on an engineered downstream transcription factor
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10200817/
https://www.ncbi.nlm.nih.gov/pubmed/37223115
http://dx.doi.org/10.1016/j.omto.2023.04.005
work_keys_str_mv AT lainscekdusko regulationofcd19cartcellactivationbasedonanengineereddownstreamtranscriptionfactor
AT goloburbancanja regulationofcd19cartcellactivationbasedonanengineereddownstreamtranscriptionfactor
AT mikolicveronika regulationofcd19cartcellactivationbasedonanengineereddownstreamtranscriptionfactor
AT pantoviczaligjelica regulationofcd19cartcellactivationbasedonanengineereddownstreamtranscriptionfactor
AT malensekspela regulationofcd19cartcellactivationbasedonanengineereddownstreamtranscriptionfactor
AT jeralaroman regulationofcd19cartcellactivationbasedonanengineereddownstreamtranscriptionfactor